局部晚期子宫颈癌新辅助化疗疗效分析

目的 探讨Ⅰb2~Ⅱb期子宫颈癌新辅助化疗的疗效.方法 回顾性分析手术治疗的84例Ⅰb2~Ⅱb期子宫颈癌患者的病历资料,患者术前均行1~3次静脉或动脉化疗,通过比较和分析化疗前后病灶进展情况、血清鳞状细胞癌抗原(SCC-Ag)值以及术后的总生存率和3年无病生存率,进而评价新辅助化疗的疗效.结果 84例患者化疗有效率为82.1%,完全缓解5例,部分缓解64例,病情稳定13例,疾病进展2例;化疗效果与临床分期、病理类型、肿瘤大小均无关(P﹥0.05);新辅助化疗后患者SCC-Ag水平明显下降(P﹤0.001);随访患者3年总生存率及无病生存率均为93%.结论 子宫颈癌新辅助化疗安全有效,可以有效缩小病灶,提高患者的预后,具有重要的临床意义.

Analysis of clinical efficacy of neoadjuvant chemotherapy in locally advanced cervical cancer

Objective To investigate the efficacy of neoadjuvant chemotherapy in stageⅠ b2~Ⅱb cervical cancer pa-tients. Method The medical records of 84 stage Ib2~Ⅱb cervical cancer patients who had undergone surgery were retro-spectively analyzed. All these patients were treated with one to three courses of venous chemotherapy or arterial chemo-therapy before surgery. The efficacy of neoadjuvant chemotherapy was assessed by comparing and analyzing the progress of the lesion before and after chemotherapy, the serum levels of squamous cell carcinoma antigen (SCC-Ag), and the 3-year disease-free survival (DFS) and overall survival after surgery. Result Of the 84 patients, the effective rate of chemo-therapy was 82.1%, 5 patients achieved complete response, 64 patients achieved partial response, 13 patients had stable disease, and 2 patients had progressive disease. The effect of chemotherapy was not correlated with clinical stage, patho-logical type and tumor size (P>0.05);the SCC-Ag levels decreased significantly after the treatment of neoadjuvant chemo-therapy (P<0.001). Both the 3-year overall survival rate and disease-free survival rate were both 93%. Conclusion Neo-adjuvant chemotherapy is safe and effective, can significantly reduce tumor size and improve prognosis in patients with cervical cancer. It has significant therapeutic values.